Invivyd, Inc. Files 8-K

Ticker: IVVD · Form: 8-K · Filed: May 12, 2025 · CIK: 1832038

Invivyd, INC. 8-K Filing Summary
FieldDetail
CompanyInvivyd, INC. (IVVD)
Form Type8-K
Filed DateMay 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing

TL;DR

Invivyd filed a standard 8-K, no major news.

AI Summary

Invivyd, Inc. filed an 8-K on May 12, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial details or material events beyond the standard reporting requirements for this form. The company was formerly known as Adagio Therapeutics, Inc., with a name change effective November 12, 2020.

Why It Matters

This 8-K filing indicates routine corporate reporting by Invivyd, Inc., without disclosing new material information that would typically impact stock price.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no new material information, indicating low immediate risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Invivyd, Inc.?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of May 12, 2025.

When was Invivyd, Inc. formerly known as?

Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc.

What is the effective date of Invivyd, Inc.'s name change?

The date of the name change from Adagio Therapeutics, Inc. to Invivyd, Inc. was November 12, 2020.

What is the principal executive office address for Invivyd, Inc.?

The principal executive office address for Invivyd, Inc. is 1601 Trapelo Road, Suite 178, Waltham, MA 02451.

Does this filing disclose any specific financial results or material events?

This filing does not appear to disclose specific financial results or material events beyond the standard reporting categories of 'Other Events' and 'Financial Statements and Exhibits'.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding Invivyd, Inc. (IVVD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing